The post Top Bitcoin Mining Stocks Soar Over US Winter Storm Hashrate Decline appeared on BitcoinEthereumNews.com. Bitcoin mining stocks saw a significant bump The post Top Bitcoin Mining Stocks Soar Over US Winter Storm Hashrate Decline appeared on BitcoinEthereumNews.com. Bitcoin mining stocks saw a significant bump

Top Bitcoin Mining Stocks Soar Over US Winter Storm Hashrate Decline

Bitcoin mining stocks saw a significant bump on Wednesday after the US winter storm forced some companies to wind down operations, leading to lower block competition and more profitable mining operations.

Shares of several major mining companies posted double-digit gains over the past 24 hours. TeraWulf rose about 11%, Iren Limited gained 14% and Cipher Mining climbed about 13%, according to data from Barchart.

The rally occurred days after the Bitcoin network’s hashrate sank to a seven-month low of 663 exahashes per second (EH/s) on Sunday, a 40% drop in two days due to a severe winter storm battering the US.

The hashrate recovered to 814 EH/s on Wednesday, but has yet to recover to the 1.1 zettahash per second (ZH/s) level before the weekend decline, data from Coinwarz shows.

Bitcoin hashrate in EH/S, one-month chart. Source: Coinwarz

A lower hashrate signals that fewer miners are online, reducing the competition for mining a block on the Bitcoin network, making Bitcoin (BTC) mining more profitable for miners who stay online.

Bitcoin mining stock performance. Source: Barchart

Related: Bitcoin rallies, ETF flows rebound as US crypto policy stalls: Finance Redefined

The Bitcoin hash price index, a benchmark for measuring miner profitability through the revenue generated per terahash, also points to more lucrative mining conditions.

The Bitcoin hashprice index rose to $0.040 per terahash per day on Wednesday, up from $0.038 TH/s per day, according to the HashrateIndex.

Bitcoin hashprice index in USD, one-week chart. Souce: Hashrateindex

Related: Crypto loses speculative edge as AI and robotics attract capital: Delphi

Bitcoin miners wind down operations amid US winter storm

The improvement highlights how large, well-capitalized mining companies can benefit during temporary network disruptions, while smaller or less efficient operations may be forced offline.

The US winter storm forced multiple Bitcoin mining companies to reduce operations to support the power grid, said Julio Moreno, head of research at data platform CryptoQuant.

This included a daily Bitcoin production decrease to 12 BTC from 22 BTC for CleanSpark, a 16 BTC-to-3 BTC reduction for Riot Platforms, a decline to 7 BTC from 45 BTC for Marathon Digital Holdings and a drop to 6 BTC from 18 BTC mined daily by Iren, wrote Moreno in a Monday X post.

Daily Bitcoin production for CleanSpark, Riot, Marathon Digital, Iren. Source: Julio Moreno

The extreme winter weather in the US “punished weak mining operations,” which is another reason for the sharp decline in global hash rate, according to Bitcoin mining ecosystem Braiins.

“Winter punishes poor preparation and rushed decisions,” wrote Braiins in a Tuesday X post, warning miners that most equipment damage happens when mining machines are restarted in freezing temperatures, or the facilities lack proper airflow and temperature control.

Magazine: Bitcoin mining industry ‘going to be dead in 2 years’ — Bit Digital CEO

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Source: https://cointelegraph.com/news/top-bitcoin-mining-stocks-soar-us-winter-hashrate-decline?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26